Startup profile · funding coverage
Stipple Bio
Stipple Bio discovers tumor-specific epitopes with its Pointillist platform to develop precision oncology antibodies.
Stage
See coverage
Status
private
Coverage
full
Why Stipple Bio is interesting
Epitope-level (not just protein-level) tumor targeting could widen the therapeutic window for solid tumors — a16z backed from seed through an oversubscribed $100M Series A.
Key facts
- Series A (Apr 2026): $100M co-led by a16z Bio+Health, RA Capital, Nextech Invest — GlobeNewswire, BioSpace
- Precision oncology using Pointillist epitope-discovery platform; lead asset STP-100 entering clinic
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24
Investors in our directory
Funds linked from Stipple Bio's profile — open a fund page for stage focus and related deal articles.
Industries
Healthtech Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Stipple Bio's financing or category context.
Last updated: 2026-07-24